OS Therapies Inc
OSTX1.535USD
-0.065-4.06%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
51.07MMarket Cap
LossP/E TTM
More Details of OS Therapies Inc Company
OS Therapies Incorporated is a clinical-stage oncology company focused on the identification, development, and commercialization of new class immunotherapy candidates for solid tumors, beginning with osteosarcoma and other solid tumors. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer.
OS Therapies Inc Info
Ticker SymbolOSTX
Company nameOS Therapies Inc
IPO dateAug 01, 2024
CEORomness (Paul A)
Number of employees4
Security typeOrdinary Share
Fiscal year-endAug 01
Address15825 Shady Grove Road
CityROCKVILLE
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code20850
Phone14102977793
Websitehttps://ostherapies.com/
Ticker SymbolOSTX
IPO dateAug 01, 2024
CEORomness (Paul A)
Company Executives of OS Therapies Inc
Name
Name/Position
Position
Shareholding
Change
Mr. John Ciccio
Mr. John Ciccio
Independent Director
Independent Director
237.92K
--
Dr. Robert G. Petit, Ph.D.
Dr. Robert G. Petit, Ph.D.
Chief Medical Officer, Chief Scientific Officer
Chief Medical Officer, Chief Scientific Officer
200.00K
--
Christopher p Acevedo ,
Christopher p Acevedo ,
Chief Financial Officer
Chief Financial Officer
109.38K
--
Mr. Gerald E. Commissiong
Mr. Gerald E. Commissiong
Chief Business Officer
Chief Business Officer
--
--
Mr. Paul A. Romness
Mr. Paul A. Romness
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. Karim Galzahr
Mr. Karim Galzahr
Director
Director
--
--
Mr. Olivier R. Jarry
Mr. Olivier R. Jarry
Independent Director
Independent Director
--
--
Ms. Avril Mckean Dieser, J.D.
Ms. Avril Mckean Dieser, J.D.
Independent Director
Independent Director
--
--
Dr. Theodore F. Search, Pharm.D.
Dr. Theodore F. Search, Pharm.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. John Ciccio
Mr. John Ciccio
Independent Director
Independent Director
237.92K
--
Dr. Robert G. Petit, Ph.D.
Dr. Robert G. Petit, Ph.D.
Chief Medical Officer, Chief Scientific Officer
Chief Medical Officer, Chief Scientific Officer
200.00K
--
Christopher p Acevedo ,
Christopher p Acevedo ,
Chief Financial Officer
Chief Financial Officer
109.38K
--
Mr. Gerald E. Commissiong
Mr. Gerald E. Commissiong
Chief Business Officer
Chief Business Officer
--
--
Mr. Paul A. Romness
Mr. Paul A. Romness
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. Karim Galzahr
Mr. Karim Galzahr
Director
Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Einodmil LLC
7.54%
Romness (Paul A.)
7.02%
Ayala Pharmaceuticals Inc
6.15%
Satterfield (Thomas A Jr)
4.99%
CM Management, LLC
1.14%
Other
73.17%
Shareholders
Shareholders
Proportion
Einodmil LLC
7.54%
Romness (Paul A.)
7.02%
Ayala Pharmaceuticals Inc
6.15%
Satterfield (Thomas A Jr)
4.99%
CM Management, LLC
1.14%
Other
73.17%
Shareholder Types
Shareholders
Proportion
Individual Investor
14.31%
Corporation
13.68%
Investment Advisor
2.10%
Investment Advisor/Hedge Fund
1.55%
Hedge Fund
0.55%
Research Firm
0.24%
Other
67.56%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
22
957.53K
2.86%
+502.43K
2025Q2
23
9.77M
34.77%
+2.15M
2025Q1
22
7.75M
30.50%
+442.25K
2024Q4
17
4.66M
21.86%
+177.62K
2024Q3
14
5.14M
25.63%
+5.14M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Einodmil LLC
2.65M
7.92%
-10.00K
-0.38%
Jul 29, 2025
Romness (Paul A.)
2.47M
7.37%
--
--
Aug 20, 2025
Ayala Pharmaceuticals Inc
2.16M
6.45%
+2.16M
--
Apr 09, 2025
Satterfield (Thomas A Jr)
1.76M
5.24%
+751.34K
+74.76%
Jun 30, 2025
CM Management, LLC
375.00K
1.12%
+75.00K
+25.00%
Jun 30, 2025
Search (Theodore F. Pharm.D.)
237.92K
0.71%
--
--
Aug 20, 2025
Ciccio (John)
237.92K
0.71%
--
--
Aug 20, 2025
Petit (Robert G)
200.00K
0.6%
--
--
Aug 20, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Micro-Cap ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of OS Therapies Inc?
The top five shareholders of OS Therapies Inc are:
Einodmil LLC holds 2.65M shares, accounting for 7.92% of the total shares.
Romness (Paul A.) holds 2.47M shares, accounting for 7.37% of the total shares.
Ayala Pharmaceuticals Inc holds 2.16M shares, accounting for 6.45% of the total shares.
Satterfield (Thomas A Jr) holds 1.76M shares, accounting for 5.24% of the total shares.
CM Management, LLC holds 375.00K shares, accounting for 1.12% of the total shares.
Einodmil LLC holds 2.65M shares, accounting for 7.92% of the total shares.
Romness (Paul A.) holds 2.47M shares, accounting for 7.37% of the total shares.
Ayala Pharmaceuticals Inc holds 2.16M shares, accounting for 6.45% of the total shares.
Satterfield (Thomas A Jr) holds 1.76M shares, accounting for 5.24% of the total shares.
CM Management, LLC holds 375.00K shares, accounting for 1.12% of the total shares.
What are the top three shareholder types of OS Therapies Inc?
The top three shareholder types of OS Therapies Inc are:
Einodmil LLC
Romness (Paul A.)
Ayala Pharmaceuticals Inc
Einodmil LLC
Romness (Paul A.)
Ayala Pharmaceuticals Inc
How many institutions hold shares of OS Therapies Inc (OSTX)?
As of 2025Q3, 22 institutions hold shares of OS Therapies Inc, with a combined market value of approximately 957.53K, accounting for 2.86% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -31.91%.
What is the biggest source of revenue for OS Therapies Inc?
In --, the -- business generated the highest revenue for OS Therapies Inc, amounting to -- and accounting for --% of total revenue.
